Laboratorios Farmaceuticos Rovi Balance Sheet Health
Financial Health criteria checks 5/6
Laboratorios Farmaceuticos Rovi has a total shareholder equity of €558.2M and total debt of €112.2M, which brings its debt-to-equity ratio to 20.1%. Its total assets and total liabilities are €877.8M and €319.7M respectively. Laboratorios Farmaceuticos Rovi's EBIT is €212.6M making its interest coverage ratio 69.7. It has cash and short-term investments of €17.6M.
Key information
20.1%
Debt to equity ratio
€112.19m
Debt
| Interest coverage ratio | 69.7x |
| Cash | €17.55m |
| Equity | €558.19m |
| Total liabilities | €319.66m |
| Total assets | €877.85m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ROVI N's short term assets (€553.8M) exceed its short term liabilities (€221.5M).
Long Term Liabilities: ROVI N's short term assets (€553.8M) exceed its long term liabilities (€98.2M).
Debt to Equity History and Analysis
Debt Level: ROVI N's net debt to equity ratio (17%) is considered satisfactory.
Reducing Debt: ROVI N's debt to equity ratio has increased from 7.2% to 20.1% over the past 5 years.
Debt Coverage: ROVI N's debt is well covered by operating cash flow (112.5%).
Interest Coverage: ROVI N's interest payments on its debt are well covered by EBIT (69.7x coverage).